At a time when economic wisdom is seen as lying in allowing unrestrained play of economic power and cutting social sector spending, here is a report emphasising the economic sense in addressing hunger, especially child malnutrition. It also brings out the positive impact of employment guarantee scheme, which has been a thrust area of the UPA government but has seen a cut in allocation in Budget proposals for 2012-13. The report...

West Bengal: The murder of two CPI(M) leaders in Bardhaman district points to an increase in political violence in the State. THE brutal murder of Pradip Tah, a former legislator belonging to the Communist Party of India (Marxist), or the CPI(M), and Kamal Gayen, another senior leader of the party, in broad daylight, allegedly by Trinamool Congress supporters, in West Bengal's Bardhaman district on February 22 once again points to an...

Token relief to individual taxpayers will cost the exchequer Rs. 4,500 crore In a “pragmatic and domestic growth-oriented” budgetary exercise aimed at shoring up investor confidence and investment, Union Finance Minister Pranab Mukherjee on Friday sought to tap indirect taxes, especially service tax, to rake in an additional Rs. 45,940 crore into his kitty. Presenting the budget for 2012-13 in Parliament, Mr. Mukherjee provided a token relief to individual taxpayers that will cost...

-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision.  The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...

In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer's patented anti-cancer drug, Nexavar, bringing down its price by 97%. In the first-ever case of compulsory licencing approval, the Indian Patent Office on Monday cleared the application of Hyderabad's Natco Pharma to sell generic drug Nexavar,...